CD30 e-Monograph

The Role of CD30: New Frontiers in Targeting Therapy for Malignant Lymphomas
The Role of CD30: New Frontiers in Targeting Therapy for Malignant Lymphomas
CME, CPE, CNE
Anton Hagenbeek, MD, PhD – Activity Chair; Tim Illidge, PhD, MRCP, FRCR, FRCPath; Anas Younes, MD
Release Date: October 21, 2016
Expiration Date: October 21, 2017

The rapid pace of scientific advances in lymphoma research makes it challenging for clinicians to stay up-to-date on the latest treatment options and ongoing clinical trials. To meet this challenge, a panel of lymphoma experts has provided the latest information on current and future developments in the treatment of CD30+ lymphomas and on novel therapeutic options that target CD30 in HL. Summaries of recent clinical trials studying CD30-targeted therapy in other lymphoma subtypes will address safety and efficacy data in these diseases.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology

View Only, CE ExpiredView Only, No Credit
 
Key Issues in the Treatment of Lymphoma: The Role of CD30 in Diagnosis and Management
Key Issues in the Treatment of Lymphoma: The Role of CD30 in Diagnosis and Management
CME, CPE, CNE
Anton Hagenbeek, MD, PhD – Program Chair; Francesco d’Amore, MD; Stefano Pileri, MD; Anas Younes, MD
Release Date: September 30, 2015
Expiration Date: September 30, 2016

With the advances made in frontline multiagent chemotherapy, Hodgkin lymphoma (HL) is deemed to be a highly curable disease. Nonetheless, advanced HL remains a challenge as 10% of patients will not achieve a complete remission and 20–30% of patients who initially responded will experience a relapse. This activity brings together leading world experts in lymphoma to discuss some of the most talked about issues and ongoing clinical trials in the treatment of HL today.

Provided by MediCom Worldwide, Inc.
This activity has been supported by an educational grant from Takeda Oncology.
MediCom Worldwide, Inc. acknowledges support from The Leukemia & Lymphoma Society
View Only, CE ExpiredView Only, No Credit
 

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved